CG Oncology, Inc.
Close on Oct 19, 2026
- Market cap
- $5.29B
- P/E (TTM)
- –
- Dividend yield
- –
About CG Oncology
Biological Products, (No Diagnostic Substances), SIC 2836
CG Oncology is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing cretostimogene grenadenorepvec, an oncolytic immunotherapy designed for bladder cancer. The investigational candidate features a dual mechanism of action that eliminates cancer cells through selective replication and prompts an anti-tumor immune response. Operating in the biopharmaceutical sector, the company focuses on bladder cancer therapeutics. Its target patient populations include individuals afflicted with high-risk and intermediate-risk non-muscle invasive bladder cancer, such as patients who are BCG-unresponsive, BCG-exposed, or BCG-naïve.
The company focuses its clinical pipeline on non-muscle invasive bladder cancer across diverse disease stages, addressing potential patient populations that range up to 150,000 individuals. Operations and clinical development activities are centered in the United States. CG Oncology maintains its principal executive offices and corporate headquarters in Irvine, California.
Summary of the business section of CG Oncology's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CG Oncology, Inc.
- Headquarters
- Dallas, TX
- Address
- 3000 Pegasus Park Drive, Suite 1640 75247
- Phone
- (949) 409-3700
- Website
- cgoncology.com
- Employees
- 142, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Irvine, California
Stock & identifiers
- Ticker
- CGON
- Exchange
- Nasdaq
- IPO date
- Jan 25, 2024
- Shares outstanding
- 89M, Aug 5, 2026
- Public float
- $1.70B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1991792
- CUSIP
- 156944100
- ISIN
- US1569441009
- EIN
- 37-1611499
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Arthur Kuan | Chief Executive Officer, Director | 200,763 |
| Joshua F. Patterson | See Remarks | – |
| James M. Detore | Chief Financial Officer | – |
| Ambaw Bellete | President and COO | – |
| Vijay Kasturi | Chief Medical Officer | 1,315 |
| Bob Lapetina | See Remarks | – |
| Corleen M. Roche | CFO | 2,000 |
| Leonard E. Post | Director | 0 |
| James Mulay | Director | 0 |
| Brian Guan-Chyun Liu | Director | 1,886,236 |
| Susan E. Graf | Director | – |
| Victor Edward Tong Jr | Director | – |
| Christina Rossi | Director | – |
| Hong Fang Song | Director | 7,039,077 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Arthur Kuan | $11.93M | $28.62M | $2.33M | $112 | $131 |
| FY2024 Arthur Kuan | $11.17M | $23.44M | $7.54M | $77 | $98 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 142 employees, all of whom were full-time, 85 of whom were engaged in research and development activities and 22 of whom were engaged in commercial readiness activities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 25, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 22, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |